Approved Indications Of Major Myeloma Drugs

Drug	Company	Year Approved	Description
Kyprolis carfilzomib	Amgen	2012	Administered as single agent in patients with at least one prior line of therapy; or combined with dexamethasone alone or dexamethasone plus Revlimid or an anti-CD38 antibody in patients with 1-3 prior lines of therapy
Ninlaro ixazomib	Takeda	2015	Combined with Revlimid in second-line and later myeloma
Velcade bortezomib	Takeda	2003	Treatment of multiple myeloma

Drug	Company	Year Approved	Description
Pomalyst pomalidomide	BMS	2013	Given as combination with dexamethasone after at least two prior lines of therapy that include Revlimid and a proteasome inhibitor in patients with disease progression on or within 60 days after completing their last therapy
Revlimid lenalidomide	BMS	2005	Myeloma generally, combined with dexamethasone; also in myeloma maintenance after autologous stem cell transplant

Drug	Company	Year Approved	Description
Darzalex daratumumab	J&J	2015	Newly diagnosed patients ineligible for stem cell transplant and relapsed/refractory patients combined with dexamethasone plus an IMiD or a proteasome inhibitor
Darzalex Faspro daratumumab and hyaluronidase-fihj	J&J	2020	Subcutaneous version of Darzalex
Sarclisa isatuximab	Sanofi	2020	Combined with Pomalyst and dexamethasone in patients with at least two prior therapies that include Revlimid and a proteasome; combined with Kyprolis and dexamethasone in patients with 1-3 prior lines of therapy

Drug

Company

Year Approved

Description

Abecma idecabtagene

vicleucel

BMS/
2seventybio

2021

Relapsed/refractory disease after at least four lines of therapy that include a proteasome inhibitor, an IMiD and a CD38-directed monoclonal antibody

Carvykti ciltacabtagene

autoleucel

J&J/
Legend Biotech

2022

Relapsed/refractory disease after at least four lines of therapy that include a proteasome inhibitor, an IMiD and a CD38-directed monoclonal antibody

Tecvayli teclistamab-cqyv

J&J

2022

Relapsed/refractory disease after at least four lines of therapy that include a proteasome inhibitor, an IMiD and a CD38-directed monoclonal antibody

Drug	Company	Year Approved	Description
Empliciti elotuzumab	BMS	2015	Anti-SLAMF7 monoclonal antibody combined with Revlimid and dexamethasone in patients with 1-3 prior therapies; combined with Pomalyst and dexamethasone in patients with at least two prior therapies including Revlimid and a proteasome inhibitor
Xpovio selinexor	Karyopharm	2019	Nuclear export inhibitor combined with Velcade and dexamethasone in second-line and later myeloma; combination with dexamethasone in patients with fifth-line and later disease that is refractory to at least two proteasome inhibitors, at least two IMiDs and an anti-CD38 antibody

Myeloma Market Snapshot: Backlogs Dog BCMA CAR-Ts As Treatment Paradigm Evolves